AntiCancer Inc., of San Diego, received U.S. Patent No. 7,264,819, titled "Lyase treatment for P. carinii." The company is in preclinical development with a recombinant bacterial protein drug, PEG-methioninase (methionine lyase), for cancer treatment and is seeking a partner to develop that drug for Pneumocystis carinii infections in AIDS patients.
Biodel Inc., of Danbury, Conn., received a notice of allowance for a patent encompassing VIAject and VIAtab, its two product candidates in clinical trials. Both emerged from the company's VIAdel technology.
BioNanomatrix Inc., of Philadelphia, was issued U.S. Patent No. 7,217,562 B2, which covers a technique for the integration of nanofluidic channels with sample delivery systems, enabling single molecules of DNA, RNA or other proteins to be separated out from standard laboratory samples for direct imaging and analysis. The company licensed the technology included in the patent from Princeton University.
CODA Genomics Inc., of Laguna Hills, Calif., received U.S. Patent No. 7,262,031, titled "Method for Producing a Synthetic Gene or Other DNA Sequence," which covers a global optimization method for the choice of DNA code to make a given protein. CODA licensed exclusive rights to the patent from the University of California.
DOR BioPharma Inc., of Miami, received a notice of allowance for a patent application, titled "Topical Azathioprine for the Treatment of Oral Autoimmune Diseases." It covers claims for treatment and prevention of oral graft-vs.-host disease with locally or topically applied immunosuppressive drug azathioprine.
Helix BioPharma Corp., of Aurora, Ontario, received U.S. Patent No. 7,264,800, which describes a method and composition for combining targeted DOS47 therapeutics with weekly basic chemotherapeutic drugs in adjunct treatment applications.
Idera Pharmaceuticals Inc., of Cambridge, Mass., received U.S. Patent No. 7,262,286, titled "Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs By Positional Chemical Changes." It covers oligonucleotide compounds comprising a synthetic immunostimulatory dinucleotide motif.